FDA says Mylan's EpiPen is in shortage in U.S.

(Reuters) - U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment.

from Reuters: Health News https://ift.tt/2FZD794